What the Institute does:
We established our company as a biomedical research company with laboratory equipment, housed in a state of the art facility. Currently we are in Phase I development which is focused on developing biomarkers for clinical use. In phase II, curated biomarkers will be developed into a product for clinical testing and use.
The goal for our company is develop a product pipeline that results in a biomarker panel specific to noncoding RNAs that are highly brain-specific, and harbors prognostic potential in glioblastoma cancer patients.
Our company fosters both private and academic collaborations that shared a common vision to help innovate the field towards making novel treatments for this disease.